Christopher Darr, Thomas Hilser, Claudia Kesch, Aykhan Isgandarov, Henning Reis, Milan Wahl, Isabel Kasper-Virchow, Boris A Hadaschik, Viktor Grünwald
{"title":"Immune-Checkpoint-Inhibitor Therapy-Principles and Relevance of Biomarkers for Pathologists and Oncologists.","authors":"Christopher Darr, Thomas Hilser, Claudia Kesch, Aykhan Isgandarov, Henning Reis, Milan Wahl, Isabel Kasper-Virchow, Boris A Hadaschik, Viktor Grünwald","doi":"10.1097/PAP.0000000000000373","DOIUrl":null,"url":null,"abstract":"<p><p>Immune-checkpoint-inhibitor (ICI) therapy has been one of the major advances in the treatment of a variety of advanced or metastatic tumors in recent years. Therefore, ICI-therapy is already approved in first-line therapy for multiple tumors, either as monotherapy or as combination therapy. However, there are relevant differences in approval among different tumor entities, especially with respect to PD-L1 testing. Different response to ICI-therapy has been observed in the pivotal trials, so PD-L1 diagnostic testing is used for patient selection. In addition to PD-L1 testing of tumor tissue, liquid biopsy provides a noninvasive way to monitor disease in cancer patients and identify those who would benefit most from ICI-therapy. This overview focuses on the use of ICI-therapy and how it relates to common and potential future biomarkers for patient-directed treatment planning.</p>","PeriodicalId":7305,"journal":{"name":"Advances In Anatomic Pathology","volume":"30 3","pages":"160-166"},"PeriodicalIF":5.1000,"publicationDate":"2023-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Advances In Anatomic Pathology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/PAP.0000000000000373","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/10/3 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"PATHOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Immune-checkpoint-inhibitor (ICI) therapy has been one of the major advances in the treatment of a variety of advanced or metastatic tumors in recent years. Therefore, ICI-therapy is already approved in first-line therapy for multiple tumors, either as monotherapy or as combination therapy. However, there are relevant differences in approval among different tumor entities, especially with respect to PD-L1 testing. Different response to ICI-therapy has been observed in the pivotal trials, so PD-L1 diagnostic testing is used for patient selection. In addition to PD-L1 testing of tumor tissue, liquid biopsy provides a noninvasive way to monitor disease in cancer patients and identify those who would benefit most from ICI-therapy. This overview focuses on the use of ICI-therapy and how it relates to common and potential future biomarkers for patient-directed treatment planning.
期刊介绍：
Advances in Anatomic Pathology provides targeted coverage of the key developments in anatomic and surgical pathology. It covers subjects ranging from basic morphology to the most advanced molecular biology techniques. The journal selects and efficiently communicates the most important information from recent world literature and offers invaluable assistance in managing the increasing flow of information in pathology.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
